Clinical and imaging characteristics associated with foveal neovascularization in proliferative diabetic retinopathy

Competing Interest

JBM is a consultant for Alcon, Allergan, Carl Zeiss, Sunovion, Topcon, and Genentech. DGV has been an advisor to Drusolv; is an inventor on patents of Neuroprotection held by Mass Eye and Ear. DH is a consultant for Allergan, Genetech, Omeicos Therapeutics, and has received financial support from National Eye Institute, Lions VisionGift, Commonwealth Grant, Lions International and the Macula Society. JWM is consultant for Genetech/Roche, Sunovion, KalVista Pharmaceuticals, ONL Therapeutics; has received financial support from Heidelberg Engineering, Lowy Medical Research Institute, Ltd.; is an inventor of patent - US 7,811,832 (with royalties paid by ONL Therapeutics to Massachusetts Eye and Ear), US 5,798,349, US 6,225,303, US 6,610,679, CA 2,185,644, CA 2,536,069 (with royalties paid by Valeant Pharmaceuticals to Massachusetts Eye and Ear). LAK is a consultant for Ingenia Therapeutics, CureVac AG, Pykus Therapeutics, and has received grant support from the National Eye Institute and the Department of Defense. NAP is a consultant for Regeneron, Dutch Ophthalmic, Genentech, EyePoint Pharmaceuticals, Alcon Vision. MY, FR, XD, MG, IG, KMO, CFB, IP, IS, IL, FV, and JR have no relevant financial disclosures.

留言 (0)

沒有登入
gif